Diabetic Foot Ulcers Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Diabetic Foot Ulcers Pipeline Insight 2024" report provides comprehensive insights about 30+ companies and 34+ pipeline drugs in the Diabetic Foot Ulcers pipeline landscape. It covers the Diabetic Foot Ulcers pipeline drug profiles, including Diabetic Foot Ulcers clinical trials and nonclinical stage products. It also covers the Diabetic Foot Ulcers pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Diabetic Foot Ulcers Pipeline Report
• DelveInsight's Diabetic Foot Ulcers Pipeline analysis depicts a robust space with 30+ active players working to develop 34+ pipeline treatment therapies.
• The leading Diabetic Foot Ulcers Companies include NovaLead Pharma, Helixmith, ShangHai HaiHe Pharmaceutical, Beyond Air, TaiGen Biotechnology, RHEACELL, TaiGen Biotechnology, Technophage, Transwell Biotech, Roche, Chiesi Farmaceutici, Aurealis Therapeutics, ZZ Biotech, APstem Therapeutics, Charsire Biotechnology Corporation, and others.
• Promising Diabetic Foot Ulcers Companies include AUP 16, CSTC 1, and others.
• May 2024:- ETS Wound Care LLC- A Randomized Controlled Clinical Trial Evaluating The Efficacy Of A Borate-Based Bioactive Glass Advanced Wound Matrix And Standard Of Care Versus Standard Of Care Alone. This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC treatments for Diabetic Foot Wounds.
• May 2024:- Piomic Medical- The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure of the COMS One device to a sham-control device at 12 weeks post-application, when each is administered in conjunction with standard of care (SOC) in the treatment of DFUs.
• May 2024:- ConvaTec Inc.- A Prospective, Multi-center Observational Study to Investigate the Safety and Effectiveness of Sterilized, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers. This is a prospective, multi-center observational study . The trial will include 30 completed subjects at three (3) experienced clinical centers in the United States. The estimated enrollment period is 13 weeks. After completing a screening , the subjects will be enrolled and receive treatment followed for at least 12 weeks.
• May 2024:- Novalead Pharma Pvt Ltd.-An Interventional, Placebo-Controlled, Randomized, Double-blinded Dose Comparison, Phase I/II Study to Determine the Safety and Efficacy of a New Gel Formulation of Esmolol Hydrochloride (Galnobax®) for the Treatment of Diabetic Foot Ulcer (DFU). The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU). The study will compare number and types of adverse events occured, rates of wound closure and percentage of wounds closed in Galnobax treated groups versus placebo group.

Request a sample and discover the recent breakthroughs happening in the Diabetic Foot Ulcers Pipeline landscape @ Diabetic Foot Ulcers Pipeline Outlook Report- https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Foot Ulcers Overview
A Diabetic Foot Ulcerss is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible.

Diabetic Foot Ulcers Emerging Drugs Profile

• AUP 16: Aurealis Therapeutics
AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector containing three therapeutic proteins (FGF2, IL4, and CSF1), produced continuously at the site of the wound, providing a combination biologic treatment in one product.

• CSTC 1: Charsire Biotechnology Corporation
CSTC 1 is being developed by Charsire Biotechnology, for the treatment of diabetic foot ulcer.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Diabetic Foot Ulcers.

For further information, refer to the detailed Diabetic Foot Ulcers Drugs Launch, Diabetic Foot Ulcers Developmental Activities, and Diabetic Foot Ulcers News, click here for Diabetic Foot Ulcers Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Foot Ulcers Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for Diabetic Foot ulcers. The companies which have their Diabetic Foot Ulcers drug candidates in the most advanced stage, i.e. Phase II include, Charsire Biotechnology Corporation.

Find out more about the Diabetic Foot Ulcers Pipeline Segmentation, Therapeutics Assessment, and Diabetic Foot Ulcers Emerging Drugs @ Diabetic Foot Ulcers Treatment Landscape- https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diabetic Foot Ulcers Pipeline Report
• Coverage- Global
• Diabetic Foot Ulcers Companies- NovaLead Pharma, Helixmith, ShangHai HaiHe Pharmaceutical, Beyond Air, TaiGen Biotechnology, RHEACELL, TaiGen Biotechnology, Technophage, Transwell Biotech, Roche, Chiesi Farmaceutici, Aurealis Therapeutics, ZZ Biotech, APstem Therapeutics, Charsire Biotechnology Corporation, and others.
• Diabetic Foot Ulcers Companies- AUP 16, CSTC 1, and others
• Diabetic Foot Ulcers Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Diabetic Foot Ulcers Pipeline Companies and Therapies, click here @ Diabetic Foot Ulcers Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Diabetic Foot Ulcers: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Foot Ulcers - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Diabetic Foot Ulcers Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. CSTC 1: Charsire Biotechnology Corporation
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical/Discovery Stage Products
19. AP Skin 01: APstem Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Diabetic Foot Ulcers Key Companies
23. Diabetic Foot Ulcers Key Products
24. Diabetic Foot Ulcers- Unmet Needs
25. Diabetic Foot Ulcers- Market Drivers and Barriers
26. Diabetic Foot Ulcers- Future Perspectives and Conclusion
27. Diabetic Foot Ulcers Analyst Views
28. Diabetic Foot Ulcers Key Companies
29. Appendix

Got Queries? Find out the related information on Diabetic Foot Ulcers Mergers and acquisitions, Diabetic Foot Ulcers Licensing Activities @ Diabetic Foot Ulcers Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/diabetic-foot-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://www.wowonder.xyz/read-blog/65223
https://diccut.com/germandennydones
https://us.newyorktimesnow.com/dennydones9193
https://www.mymeetbook.com/germanydennydones
https://wiwonder.com/1716272393254738_2674
https://www.japanesewomenorg.com/read-blog/15585
https://tannda.net/read-blog/62770
https://evahno.com/read-blog/22402
https://www.pickmemo.com/read-blog/307268
https://ai.ceo/read-blog/132421
https://www.truthsocialviet.com/read-blog/58205
https://hanzuzhisheng.com/read-blog/489
https://www.testimonyforgod.com/read-blog/3019
https://www.skillsire.com/germandennydones
https://meetplayer.com/8a48fed02
https://zekond.com/read-blog/37531
https://shareyoursocial.com/germanydennydones
https://www.snipesocial.co.uk/dennydones9911
https://social.studentb.eu/read-blog/182065

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.